Atox Bio Announces Successful Completion of Phase 1 for AB103, a Novel Immunomodulator Being Developed for Severe Bacterial Infections and Sepsis  
5/12/2011 9:34:51 AM

NESS ZIONA, Israel--(BUSINESS WIRE)--Atox Bio Inc. today announced that it successfully completed a phase 1 clinical study of AB103, a novel therapy for the treatment of severe bacterial infections and sepsis.

The trial was designed to evaluate the safety, tolerability and pharmacokinetics of AB103. It was a double blind, placebo controlled study that included 25 healthy volunteers receiving escalating single doses of AB103. The study was conducted at the University of Maryland in Baltimore, US.